Experience

Represented U.S. pharmaceutical corporation in a BPCIA dispute related to monoclonal antibody therapeutic used to treat immune system conditions.*

Represented U.S. pharmaceutical corporation in a Biologics Price Competition and Innovation (BPCIA) dispute related to its billion-dollar blockbuster monoclonal antibody therapeutic used to treat immune system conditions.

Related Practices

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Biologics

*Matter handled prior to joining Finnegan.

Related Experiences

AbbVie Inc. v. Amgen Inc.

AbbVie Inc.

AbbVie Inc. v. Boehringer Ingelheim International GmbH

AbbVie Inc.

AbbVie Inc. et al v. Alvotech hf.

AbbVie Inc. et al

Finnegan successfully represents U.S. pharmaceutical company in an arbitration

Represented U.S. software company in patent infringement and invalidity dispute*

Represented a telecoms company in its defence of a patent for the use of ‘keepalive’ packets of data*

Arbitration victory for major U.S. pharmaceutical company

Represented a pharmaceutical company before German Civil Patent Courts*

Mitsubishi Tanabe Pharma Corporation v. Shanghai Auzone Biological Technology Co., Ltd et al.

Mitsubishi Tanabe Pharma Corporation

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.